1. |
?László L. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer. Magy Onkol, 2010, 54(4):383-394.
|
2. |
Xiang TX, Yuan Y, Li LL, et al. Aberrant promoter CpG methylation and its translational applications in breast cancer. Chin J Cancer, 2013, 32(1):12-20.
|
3. |
Shadfan A, Hellebust A, Richards-Kortum R, et al. Confocal foveated endomicroscope for the detection of esophageal carcinoma. Biomed Opt Express, 2015, 6(7):2311-2324.
|
4. |
Vukobrat-Bijedic Z, Husic-Selimovic A, Sofic A, et al. Cancer antigens (CEA and CA 19-9) as markers of advanced stage of colorectal carcinoma. Med Arch, 2013, 67(6):397-401.
|
5. |
Man YG, Schwartz A, Levine PH, et al. BP1, a putative signature marker for inflammatory breast cancer and tumor aggressiveness. Cancer Biomark, 2009, 5(1):9-17.
|
6. |
汪华, 贺静, 闫晓红, 等. BP1基因在结肠癌组织中的表达. 现代肿瘤医学, 2015, 23(14):2041-2043.
|
7. |
Park Y, Kim DS, Park KH, et al. RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin. Onkologie, 2012, 35(11):673-682.
|
8. |
刘会平, 杨磊, 丁彦青, 等. 多配体聚糖结合蛋白在大肠癌组织中的表达及其对预后的影响. 南方医科大学学报, 2015, 35(7):1003-1007.
|
9. |
Tsukahara T, Haniu H, Matsuda Y. Cyclic phosphatidic acid induces G0/G1 arrest, inhibits AKT phosphorylation, and downregulates cyclin D1 expression in colorectal cancer cells. Cell Mol Biol Lett, 2015, 20(1):38-47.
|
10. |
Delavari A, Bishehsari F, Salimzadeh H, et al. Adenoma detection rates in an opportunistic screening colonoscopy program in Iran, a country with rising colorectal cancer incidence. BMC Gastroenterol, 2014, 14:196.
|
11. |
Fu Y, Lian Y, Kim KS, et al. BP1 homeoprotein enhances metastatic potential in ER-negative breast cancer. J Cancer, 2010, (1):54-62.
|
12. |
Del Vecchio Blanco G, Paoluzi OA, Sileri P, et al. Familial colorectal cancer screening:When and what to do? World J Gastroenterol, 2015, 21(26):7944-7953.
|
13. |
Olsen AK, Coskun M, Bzorek M, et al. Regulation of APC and AXIN2 expression by intestinal tumor suppressor CDX2 in colon cancer cells. Carcinogenesis, 2013, 34(6):1361-1369.
|
14. |
Man YG, Fu SW, Schwartz A, et al. Expression of BP1, a novel homeobox gene, correlates with breast cancer progression and invasion. Breast Cancer Res Treat, 2005, 90(3):241-247.
|
15. |
Montenegro MF, Saez-Ayala M, Pinero-Madrona A, et al. Reactivation of the tumour suppressor RASSF1A in breast cancer by simultaneous targeting of DNA and E2F1 methylation. PLoS one, 2012, 7(12):e52231.
|
16. |
Maeda C, Hidaka E, Mori Y, et al. Tumor diameter is an easy and useful predictor of recurrence in stage Ⅱ colorectal cancer. Dig Surg, 2015, 32(5):338-343.
|
17. |
Trovik J, Wik E, Stefansson IM, et al. Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res, 2011, 17(10):3368-3377.
|
18. |
Chung MK, Kim HJ, Lee YS, et al. Hedgehog signaling regulates proliferation of prostate cancer cells via stathmin1. Clin Exp Med, 2010, 10(1):51-57.
|
19. |
谭明, 戴春, 丁永斌, 等. syndecan21蛋白在胃癌中的表达及其意义. 中国普外基础与临床杂志, 2008, 15(12):910-913.
|
20. |
姚宏亮, 杨竹林, 李永国, 等. 胃癌及癌旁组织中SKP2和p27蛋白表达及相互关系研究. 中国普外基础与临床杂志, 2007, 14(3):308-311.
|
21. |
Rosell R. Expression profiles and clinicopathologic features in early resected non-small-cell lung cancer. EBioMedicine, 2014, 1(2-3):103-104.
|
22. |
Liu X, Liu H, Liang J, et al. Stathmin is a potential molecular marker and target for the treatment of gastric cancer. Int J Clin Exp Med, 2015, 8(4):6502-6509.
|
23. |
Wang F, Wang LX, Li SL, et al. Downregulation of stathmin is involved in malignant phenotype reversion and cell apoptosis in esophageal squamous cell carcinoma. J Surg Oncol, 2011, 103(7):704-715.
|
24. |
Ojima T, Nezuka H, Earashi M, et al. Poor outcome of a patient with early double cancers of the stomach and sigmoid colon in which liver metastases were detected postoperatively. Gan To Kagaku Ryoho, 2014, 41(12):2425-2427.
|